An “In-House” ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes
An “In-House” ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes
Abstract The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) first reported in Wuhan has caused a global pandemic with dramatic health and socioeconomic consequences. The Coronavirus Disease 2019 (COVID-19) associated represents a challenge for health systems that had to quickly respond developing new diagnostic and therapeutic strategies. In the present work, we developed an “In House” ELISA with high sensitivity (92.2 %), specificity (100%) and precision (93.9%), with an area under the ROC curve (AUC) of 0.991, rendering the assay as an excellent serological test to correctly discriminate between SARS-COv-2 infected and non-infected individuals and study population seroprevalence. Among 758 patients evaluated for SARS-CoV-2 diagnosis in the province of Tucumán, Argentina, we found a Pearson correlation coefficient of 0.5048 between antibodies elicited against the RBD and the nucleocapsid (N) antigen. Additionally, 33.6% of individuals diagnosed with COVID-19 displayed mild levels of RBD-IgG antibodies, while 19% of the patients showed high antibody titers. Interestingly, patients with SARS-COV-2 infection over 60 years old elicited significantly higher levels of IgG antibodies against RBD compared to younger ones, while no difference was found between women and men. Surprisingly, individuals from a high altitude village displayed statistically significant higher and longer lasting anti-RBD antibodies compared to those from a city at a lower altitude, suggesting that a hypobaric hypoxia-adapted mechanism may act as a protective factor for COVID-19. To our knowledge, this is the first report correlating altitude with increased humoral immune response against SARS-Cov-2 infection.
Gustavo Mostoslavsky、Silvina Chaves、Rossana Chahla、M¨?nica Aguilar、Silvia Cazorla、Dardo Costas、Isolina Flores、Rodrigo Tomas Grau、Esteban Vera Pingitore、Diego Ploper、Benjam¨an Socias Sergio、Carolina Maldonado、Rosana Cheh¨an、Gabriela Apfelbaum、C¨|sar ¨￠vila、Agust¨an Stagnetto、Silvia Navarro、Patricia Aznar、Gabriela Perdig¨?n、Ra¨2l Mostoslavsky、Malena Alcorta、Dar Heinze、Conrado Llapur
Section of Gastroenterology, Department of Medicine, Center for Regenerative Medicine (CReM), Boston University School of MedicineInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nHospital N¨|stor Kirchner, Laboratorio de Salud P¨2blica, Sistema Provincial de Salud ¨C LSP (SiProSa). Tucum¨￠nHospital N¨|stor Kirchner, Laboratorio de Salud P¨2blica, Sistema Provincial de Salud ¨C LSP (SiProSa). Tucum¨￠nCentro de Referencia para Lactobacilos ¨C CERELA (CONICET). Tucum¨￠nHospital N¨|stor Kirchner, Laboratorio de Salud P¨2blica, Sistema Provincial de Salud ¨C LSP (SiProSa). Tucum¨￠nHospital N¨|stor Kirchner, Laboratorio de Salud P¨2blica, Sistema Provincial de Salud ¨C LSP (SiProSa). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nCentro de Referencia para Lactobacilos ¨C CERELA (CONICET). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nFacultad de Medicina ¨C Universidad Nacional de Tucum¨￠n. Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (CONICET-UNT-SiProSa). Tucum¨￠nHospital N¨|stor Kirchner, Laboratorio de Salud P¨2blica, Sistema Provincial de Salud ¨C LSP (SiProSa). Tucum¨￠nCentro de Referencia para Lactobacilos ¨C CERELA (CONICET). Tucum¨￠nThe Massachusetts General Hospital Cancer Center, Harvard Medical School, BostonHospital N¨|stor Kirchner, Laboratorio de Salud P¨2blica, Sistema Provincial de Salud ¨C LSP (SiProSa). Tucum¨￠nSection of Gastroenterology, Department of Medicine, Center for Regenerative Medicine (CReM), Boston University School of MedicineDirecci¨?n de Investigaci¨?n en Salud. Ministerio de Salud P¨2blica, Tucum¨￠n
医学研究方法预防医学基础医学
Gustavo Mostoslavsky,Silvina Chaves,Rossana Chahla,M¨?nica Aguilar,Silvia Cazorla,Dardo Costas,Isolina Flores,Rodrigo Tomas Grau,Esteban Vera Pingitore,Diego Ploper,Benjam¨an Socias Sergio,Carolina Maldonado,Rosana Cheh¨an,Gabriela Apfelbaum,C¨|sar ¨￠vila,Agust¨an Stagnetto,Silvia Navarro,Patricia Aznar,Gabriela Perdig¨?n,Ra¨2l Mostoslavsky,Malena Alcorta,Dar Heinze,Conrado Llapur.An “In-House” ELISA for SARS-CoV-2 RBD uncovers elevated immune response at higher altitudes[EB/OL].(2025-03-28)[2025-05-25].https://www.medrxiv.org/content/10.1101/2021.03.10.21252711.点此复制
评论